Inactive Instrument

Tauriga Sciences, Inc.

TAUG

US87669X2053

Pharmaceuticals

Delayed OTC Markets Other stock markets 10:14:36 2024-05-03 EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	0.00%

2022	Tauriga Sciences Inc. Receives its 10,000th E-Commerce Order	CI
2022	Tauriga Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	CI

Tauriga Sciences, Inc. Reports Earnings Results for the Full Year Ended March 31, 2020

June 30, 2020 at 09:19 am

Tauriga Sciences, Inc. announced earnings results for the full year ended March 31, 2020. For the full year, the company announced sales was USD 234,389 compared to USD 57,134 a year ago. Operating loss was USD 2.039 million compared to USD 1.083 million a year ago. Net loss was USD 3.033 million compared to USD 1.097 million a year ago. Basic loss per share from continuing operations was USD 0.037 compared to USD 0.02 a year ago.

Latest news about Tauriga Sciences, Inc.

Tauriga Sciences Inc. Receives its 10,000th E-Commerce Order	22-03-25	CI
Tauriga Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-02-16	CI
Tauriga Sciences Inc. Receives its 9,000th E-Commerce Order	22-01-21	CI
Tauriga Sciences Inc. Receives Product Endorsement from the State of Alaska	21-12-21	CI
Tauriga Sciences Inc. Formally Submits its Clinical Study Protocol to the Institutional Review Board	21-12-17	CI
Tauriga Sciences, Inc. Appoints Matthew A. Shaw as Member of its Corporate Advisory Board	21-12-01	CI
Tauriga Sciences, Inc. has Changed its Name to Sublingual Technologies Inc	21-11-22	CI
Tauriga Sciences, Inc. Confirms the Commercial Launch of Its New & Improved Tauri-Gummies? Product, Kosher Certified by Orthodox Union	21-11-16	CI
Tauriga Sciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	21-11-15	CI
Tauriga Sciences, Inc. to Proceed with the Production of Its Proprietary Kratom Infused Chewing Gum	21-11-02	CI
Tauriga Sciences Inc. Enters into Strategic Alliance with Psychedelic Water	21-10-19	CI
Tauriga Sciences Inc. Commences Development of Ashwagandha Infused Chewing Gum	21-10-15	CI
Tauriga Sciences Inc. Expands its Product Offerings of Delta 8 THC Infused Gummies	21-10-08	CI
Tauriga Sciences Inc. Commences Development of Kratom Extract Infused Chewing Gum	21-10-07	CI
Tauriga Sciences, Inc. Announces Resignation of David Wolitzky from the Board of Directors	21-09-22	CI
Tauriga Sciences Inc. Products Offerings Now Available on Amazon Prime	21-09-16	CI
Tauriga Sciences Inc. Completes Funding of the Study Protocol Phase of Its Recently Initiated Clinical Trial	21-09-13	CI
Tauriga Sciences Inc. Fully Repays its $135,000 Inventory Factoring Credit Facility	21-09-03	CI
Tauriga Sciences, Inc. Initiates Clinical Trial to Examine the Effects of Cannabidiol Doses on Pregnant Women with Diagnosis of Hyperemesis Gravidarum	21-08-31	CI
Tauriga Sciences, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-16	CI
Tauriga Sciences Inc. Announces the Arrival of Product Inventory for its Enhanced Tauri-Gum Product Line	21-08-03	CI
Tauriga Sciences Inc. Introduces Two Innovative Topical Products: CBD Infused Sunscreen Spray and Acai Fragrance Moisturizing Lip Balm	21-07-12	CI
Tauriga Sciences Inc. Introduces Two Innovative Topical Products: CBD Infused Sunscreen Spray and Acai Fragrance Moisturizing Lip Balm	21-07-12	CI
Tauriga Sciences Inc. Announces Availability of its Products for Sale on Amazon.com	21-07-09	CI
Tauriga Sciences, Inc. and Think BIG, LLC Confirm the Launch of Two Limited-Edition Frank White/Tauri-Gum Versions	21-07-09	CI

Chart Tauriga Sciences, Inc.

Duration

Period

More charts

Company Profile

Tauriga Sciences, Inc. is a science, technology and consumer products company. The Company operates through its subsidiary, Tauriga Pharma Corp., which is focused on the development of a pharmaceutical product line that is synergistic with the Companyâs primary Cannabidiol (CBD) product line. The Company operates through two segments. The first division consists of all retail, wholesale and e-commerce product sales of CBD/CBG Tauri-Gum, Tauri-Gummies, and other CBD/CBG products. The second segment is the research and development division, which consists of liabilities and results from any activity relative to the progress in the development of the Companyâs Food and Drug Administration (FDA) and Investigational New Drug (IND) application for Phase II Trial of its proposed pharmaceutical-grade version of Tauri-Gum. It also developed an immune booster version of Tauri-Gum chewing gum. This product contains 60 milligrams (mg) of Vitamin C and 10mg of Elemental Zinc per piece.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+34.20%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-3.16%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+6.51%	294B
ASTRAZENECA PLC	+14.11%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.80%	168B

Other Pharmaceuticals